59698-21-4

Upstream product

• 34108-21-9 methyl cyclopropylacetate 
• 72306-36-6 methyl 2-cyclopropyl-3-aldehydeacetate 
• 17356-08-0 thiourea 
• 5239-82-7 cyclopropylacetic acid 
• 6542-60-5 2-cyclopropylacetonitrile 
• 54322-65-5 cyclopropylacetyl chloride 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 59698-20-3 5-cyclopropyl-pyrimidin-2,4-(1H,3H)-dione 
• 136160-36-6 5-Cyclopropyl-1-ethoxymethyl-6-phenylsulfanyl-1H-pyrimidine-2,4-dione 
• 136160-37-7 5-Cyclopropyl-1-ethoxymethyl-6-phenylsulfanyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 1190377-54-8 cyclobutanecarboxylic acid {3-[5-cyclopropyl-2-(3-fluoro-phenylamino)-pyrimidin-4-ylamino]-propyl}-amide 
• 1190377-57-1 thiophene-2-carboxylic acid {3-[5-cyclopropyl-2-(3-fluoro-phenylamino)-pyrimidin-4-ylamino]-propyl}-amide 
• 1190377-92-4 thiophene-2-carboxylic acid {3-[5-cyclopropyl-2-(2-fluoro-phenylamino)-pyrimidin-4-ylamino]-propyl}-amide 
• 1415227-70-1 C₂₂H₂₄FN₅OS 
• 1415227-71-2 C₂₁H₂₉N₅OS 
• 1190377-79-7 cyclobutanecarboxylic acid {3-[5-cyclopropyl-2-(3-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-propyl}-amide 
• 1190378-43-8 cyclobutanecarboxylic acid {3-[5-cyclopropyl-2-(3-1,2,4-triazol-1-ylmethyl-phenylamino)-pyrimidin-4-ylamino]-propyl}-amide 
• 1190379-46-4 cyclobutanecarboxylic acid (3-{5-cyclopropyl-2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-pyrimidin-4-ylamino}-propyl)-amide 
• 1190379-44-2 cyclobutanecarboxylic acid (3-{5-cyclopropyl-2-[4-(2-dimethylamino-methyl)-phenylamino]-pyrimidin-4-ylamino}-propyl)-amide 
• 1190379-37-3 cyclobutanecarboxylic acid {3-(5-cyclopropyl-2-(4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino)-propyl}-amide 
• 1190379-40-8 cyclobutanecarboxylic acid (3-{5-cyclopropyl-2-[4-(2H-1,2,4-triazol-1-yl)-phenylamino]-pyrimidin-4-ylamino}-propyl)-amide 

Relevant academic research and scientific papers

As Hedgehog signal transduction pyrimidine amines and pyridine amine inhibitors

The invention relates to pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors. The inhibitors are compounds with the structure represented by formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to a medicinal use of the above compounds as hedgehog signal conduction inhibitors.

Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors

A series of novel hedgehog signaling pathway inhibitors have been designed by structural modification based on the former reported scaffold of 4-(2-pyrimidinylamino)benzamide. The SAR for this series was described and many derivatives showed potent inhibitory activity. Among these compounds, compounds 12af and 12bf were identified to have high potency and optimal PK profiles. Although both of compounds 12af and 12bf did not show strong antitumor efficacy in LS-174T nude mice model, they were promising candidates as Hh signaling inhibitors due to great potency against Hh signaling pathway and outstanding PK properties, deserving further evaluation in other Hh signaling operative tumor models.

The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors

Hedgehog signaling pathway inhibitors are emerging as new therapeutic intervention against cancer. A novel series of N-(2-pyrimidinylamino) benzamide derivatives as hedgehog signaling pathway inhibitors were designed and synthesized. Most compounds presented significant inhibitory effect on hedgehog signaling pathway, among which 21 compounds exhibited more potent than vismodegib. Furthermore, compound 6a showed moderate pharmacokinetic properties in vivo, representing a promising lead compound for further exploration.

Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases

The design, synthesis and structure-activity relationships of a novel series of 2,4-diamino-5-cyclopropyl pyrimidines is described. Starting from BX795, originally reported to be a potent inhibitor of PDK1, we have developed compounds with improved selectivity and drug-like properties. These compounds have been evaluated in a range of cellular and in vivo assays, enabling us to probe the putative role of the TBK1/IKKε pathway in inflammatory diseases.

Free Radical Rearrangements in Uracil Derivatives

As part of an effort to develop general probes for radical reactions involving DNA bases, several uracil derivatives were synthesized.The rates of the cyclopropyl carbinyl rearrangement in these systems were evaluated by means of competition experiments.The results indicate that when a cyclopropyl group is substituted in the 5-position of uracil, the rearrangement occurs very slowly - with a rate constant of -1.On the other hand, the analog of the 5-hexenyl radical cyclization onto the 5,6-double bond of uracil derivatives occurs with rates which were similar to the parent process: (4.0-8.9)E4 s-1.The experimental results along with semiempirical calculations show that radicals 23 and 25 are unusually stable species.These results explain why no rearrangements are observed when a cyclopropyl-substituted thymine dimer is cleaved by reductive single electron transfer.

The synthesis of some 5-substituted and 5,6-disubstituted 2'- deoxyuridines

5-Alkyl(cycloalkyl)-2'-deoxyuridines VIa-VIf were synthesised in high yields by condensation of the corresponding silylated bases with 2-deoxy- 3,5-di-O-p-toluoyl-D-erythro-pentosyl chloride in chloroform and subsequent deblocking with sodium methoxide in